The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
REGULATORY
MSD’s 21-Valent Pneumococcal Shot Nears Japan Approval; Male Use of Silgard 9 Cleared
A Japanese health ministry panel on July 24 endorsed a series of label expansions and one new vaccine from MSD - a 21-valent pneumococcal conjugate jab known as Capvaxive overseas - paving the way for their imminent approval. The Pharmaceutical…
To read the full story
Related Article
- MSD Launches 21-Valent Pneumococcal Vaccine Capvaxive in Japan
October 30, 2025
- Japan Approves 3 New Drugs, Expands Label for Enhertu, Silgard 9 and More
August 26, 2025
- Japan Approves MSD’s 21-Valent Pneumococcal Vaccine
August 8, 2025
- Japan Panel to Review MSD’s 21-Valent Pneumococcal Shot, Silgard 9 for Male Use and More Label Expansions
July 18, 2025
- MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
- Enhertu Filed for HER2 Low or Ultralow Breast Cancer in Japan
October 7, 2024
- Opdivo-Yervoy Filed for 1st Line Use in MSI-H Colorectal Cancer in Japan
September 13, 2024
- MSD Seeks Japan Nod for 21-Valent Pneumococcal Jab for Adults
August 13, 2024
REGULATORY
- PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
- AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
- Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
- Daiichi, University of Tokyo Professor Win Japan’s PM Award for Ezharmia Development
January 20, 2026
- Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…